Breaking News

Visiox and Ocuvex Merge to Form Ophthalmic Powerhouse

Aim to emerge as a leader in the eye care sector with a strong portfolio of ophthalmic medicines.

Author Image

By: Charlie Sternberg

Associate Editor

Visiox Pharmaceuticals Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines.   The strategic combination aims to position the newly combined entity as an emerging leader in the eye care sector with a strong portfolio of ophthalmic medicines.   Visiox’s products, including OMLONTI (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters